Fortive (FTV) Q4 2025 earnings review
Core Growth Accelerates, Validating the Spin Strategy
Fortive delivered a solid finish to 2025, validating the 'New Fortive' thesis post-Ralliant spin-off. Core revenue growth accelerated to 3.3% (up from 1.9% in Q3), driven by the Intelligent Operating Solutions (IOS) segment. While top-line momentum is building, the quality of earnings shows a split: Adjusted EPS grew 12.5% to $0.90 (beating the high end), but GAAP Net Income actually fell 0.9% year-over-year. Aggressive buybacks (~8% of float retired in H2) are heavily supporting the EPS growth narrative.
🐂 Bull Case
Intelligent Operating Solutions is the engine room. Revenue grew 4.1% core, and Adjusted EBITDA margins expanded 80 basis points to 37.4%. This segment is successfully converting volume into profit.
Management is aggressively shrinking the share count. They deployed $265M in Q4 and ~$1.3B in H2 2025 toward buybacks, retiring ~8% of shares. This creates a structural tailwind for EPS.
🐻 Bear Case
Advanced Healthcare Solutions (AHS) is underperforming. While core revenue grew 1.6%, Adjusted EBITDA margins collapsed 150 basis points YoY to 26.0%, and GAAP operating profit fell nearly 10%.
Despite the 'acceleration' narrative, GAAP Net Income was down 0.9% YoY ($192M vs $193M). The double-digit Adjusted EPS growth is primarily engineered through adjustments and share count reduction, not raw net income growth.
⚖️ Verdict: 🟢
Stable/Bullish. The core growth acceleration in Q4 is the critical signal investors needed. While AHS margins are a drag, the dominant IOS segment and aggressive capital returns provide a solid floor. The initial FY26 guidance ($2.90-$3.00) implies steady continued execution.
Key Themes
Intelligent Operating Solutions (IOS) Acceleration
Accelerating. IOS is carrying the company. Core growth improved to 4.1% (up from 2.2% in Q3), and margins hit a robust 37.4%. As the largest segment (69% of Q4 revenue), its performance dictates the company's trajectory. The 5.7% growth in GAAP operating profit confirms this is high-quality growth.
Advanced Healthcare Solutions (AHS) Margin Erosion
Reversing. AHS profitability is moving in the wrong direction. Despite a return to positive core growth (+1.6%), GAAP Operating Margin fell 160 bps to 10.9% and Adjusted EBITDA margin fell 150 bps to 26.0%. Management previously cited policy headwinds, but the inability to protect margins on rising revenue is a red flag.
Share Count Reduction
Stable. The company executed an incremental $265 million in buybacks in Q4. Total H2 repurchases reached ~$1.3 billion, reducing the diluted share count from ~348M (24Q4) to ~319M (25Q4). This ~8% reduction is a primary driver of the double-digit EPS growth.
GAAP vs. Adjusted Divergence
Stable. The gap between GAAP and Adjusted results remains wide. Q4 GAAP EPS was $0.60 vs. Adjusted EPS of $0.90. The adjustments (primarily amortization and restructuring) add 50% to the bottom line number. Investors should note that 'real' GAAP net income did not grow this quarter (-0.9%).
Other KPIs
Stable. Up 2.9% YoY. Conversion remains decent but not spectacular given the adjusted earnings growth. Full year FCF of $931M is slightly down from $942M in FY24 (Continuing Ops basis), reflecting the friction costs of the separation year.
Accelerating. Cost of sales rose 9.6% YoY, significantly outpacing the 4.6% revenue growth. This gross margin pressure (gross margin compressed ~70bps to 63.1%) was offset by OpEx control in IOS, but remains a watch item.
Guidance
Accelerating (in absolute dollars). The midpoint ($2.95) implies ~9% growth over FY25's $2.71. This is consistent with the double-digit growth narrative, likely supported by continued buybacks and IOS momentum.
Key Questions
AHS Margin Recovery
Margins in Advanced Healthcare Solutions contracted 150 bps despite revenue growth. Is this a structural step-down due to mix/pricing, or were there specific one-time costs in Q4? When will margins stabilize?
Gross Margin Pressure
Cost of sales grew twice as fast as revenue in Q4 (9.6% vs 4.6%). What drove this input cost inflation, and is it related to the tariff headwinds mentioned in previous quarters?
Organic Growth vs. Buybacks in 2026
The 2026 guidance implies ~9% EPS growth. How much of this is driven by operational core growth versus the carry-over impact of the ~8% share count reduction executed in late 2025?